On Friday, Novo Nordisk A/S' (NYSE:NVO) board director Mikael Dolsten said he will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025.

Dolsten, who most recently served as the Head of R&D at Pfizer (NYSE:PFE), informed Novo Nordisk that he has decided to withdraw his candidacy to the Novo Nordisk Board of Directors, both as a member and as observer, due to recent personal circumstances unrelated to Novo Nordisk and the Novo Nordisk Foundation.

The Novo Nordisk Foundation and Novo Holdings A/S have informed Novo Nordisk that they will not propose the election of another candidate instead of Mikael Dolsten.

Novo Nordisk makes both Ozempic and Wegovy. Ozempic is a brand name for semaglutide used to treat type 2 diabetes, while Wegovy is the brand name for the same drug used for weight management.

Also Read: Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker

Instead, the Novo Nordisk Foundation and Novo Holdings intend for the incoming Novo Nordisk Board of Directors to identify and nominate two candidates in addition to the already nominated Helena Saxon to the Board of Directors at Novo Nordisk's Annual ...